Low-density lipoprotein triglyceride predicts outcomes in patients with chronic coronary syndrome following percutaneous coronary intervention according to inflammatory status.

[1]  P. Libby,et al.  The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. , 2021, European heart journal.

[2]  J. S. St. John,et al.  Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial. , 2020, JAMA cardiology.

[3]  R. Diaz,et al.  Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. , 2019, The New England journal of medicine.

[4]  H. Daida,et al.  Clinical Significance of High-Sensitivity C-Reactive Protein in Patients with Preserved Renal Function Following Percutaneous Coronary Intervention. , 2019, International heart journal.

[5]  Samin K. Sharma,et al.  Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. , 2019, Journal of the American College of Cardiology.

[6]  P. Serruys,et al.  C‐reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: Analysis from the EXCEL trial , 2019, American heart journal.

[7]  P. Libby,et al.  Low‐Dose Methotrexate for the Prevention of Atherosclerotic Events , 2019, The New England journal of medicine.

[8]  Samin K. Sharma,et al.  Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions , 2018, European heart journal.

[9]  P. Ridker,et al.  Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy , 2018, Circulation.

[10]  E. Boerwinkle,et al.  Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. , 2018, Journal of the American College of Cardiology.

[11]  Michael Miller.  Low-Density Lipoprotein Triglycerides: Widening the Atherogenic Landscape in CVD Risk Assessment. , 2018, Journal of the American College of Cardiology.

[12]  Lawrence A Leiter,et al.  Inflammatory and Cholesterol Risk in the FOURIER Trial , 2018, Circulation.

[13]  P. Libby,et al.  Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial , 2017, The Lancet.

[14]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[15]  B. Nordestgaard,et al.  Remnant Cholesterol and Triglyceride-Rich Lipoproteins in Atherosclerosis Progression and Cardiovascular Disease. , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[16]  J. Fleg,et al.  Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial. , 2016, Atherosclerosis.

[17]  P. Serruys,et al.  High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary intervention. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[18]  Paul M Ridker,et al.  Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. , 2016, European heart journal.

[19]  P. Ridker.  From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. , 2016, Circulation research.

[20]  R. Giugliano,et al.  Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT , 2015, Circulation.

[21]  B. Nordestgaard,et al.  Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.

[22]  Paul M Ridker,et al.  Inflammation in atherosclerosis: from pathophysiology to practice. , 2009, Journal of the American College of Cardiology.

[23]  Seung‐Jung Park,et al.  C-Reactive Protein and the Risk of Stent Thrombosis and Cardiovascular Events After Drug-Eluting Stent Implantation , 2009, Circulation.

[24]  J. Hubacek,et al.  Prognostic implications of C-reactive protein and troponin following percutaneous coronary intervention. , 2009, The Canadian journal of cardiology.

[25]  W. März,et al.  Low-Density Lipoprotein Triglycerides Associated With Low-Grade Systemic Inflammation, Adhesion Molecules, and Angiographic Coronary Artery Disease: The Ludwigshafen Risk and Cardiovascular Health Study , 2004, Circulation.

[26]  J. Kaski,et al.  C-reactive protein elevation and disease activity in patients with coronary artery disease. , 2004, European heart journal.

[27]  K. Kugiyama,et al.  Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. , 2000, Circulation.

[28]  I. Goldberg.  Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. , 1996, Journal of lipid research.

[29]  K. Feingold,et al.  Regulation of lipid metabolism by cytokines during host defense. , 1996, Nutrition.